Summary
Stryker Corporation's second quarter 2016 results demonstrate robust top-line growth, driven significantly by strategic acquisitions, particularly Sage Products and Physio-Control. While net sales increased substantially, the company faced some headwinds, including increased operating expenses and the ongoing impact of recall charges related to its hip stems. Despite a slight decrease in reported net earnings for the quarter, adjusted net earnings per diluted share showed strong growth, indicating the underlying operational strength. The company's financial position remains solid, supported by significant cash flows from operations and substantial debt financing to support its growth strategy. Investors should note the significant impact of acquisitions on revenue growth, particularly in the MedSurg segment, and the continued, though reduced, expenses associated with product recalls. The company has also undertaken substantial debt financing, increasing its leverage but providing resources for strategic investments. Management's focus on adjusted earnings per share highlights their emphasis on operational performance beyond one-time or acquisition-related impacts.
Financial Highlights
51 data points| Revenue | $2.84B |
| Cost of Revenue | $998.00M |
| Gross Profit | $1.84B |
| R&D Expenses | $183.00M |
| SG&A Expenses | $1.04B |
| Operating Expenses | $1.34B |
| Operating Income | $500.00M |
| Net Income | $380.00M |
| EPS (Basic) | $1.02 |
| EPS (Diluted) | $1.00 |
| Shares Outstanding (Basic) | 374.20M |
| Shares Outstanding (Diluted) | 378.50M |
Key Highlights
- 1Consolidated net sales grew by 16.8% year-over-year in Q2 2016 to $2.84 billion, with 17.0% growth on a constant currency basis. This growth was significantly boosted by acquisitions, which contributed 10.4% to constant currency sales growth.
- 2The MedSurg segment showed exceptional performance, with net sales increasing by 33.8% (34.2% constant currency) driven by acquisitions (25.7%) and underlying volume growth.
- 3Despite overall sales growth, reported net earnings decreased slightly by 3.1% to $380 million ($1.00 per diluted share) in Q2 2016, compared to $392 million ($1.03 per diluted share) in Q2 2015.
- 4Adjusted net earnings per diluted share saw robust growth, increasing by 15.8% to $1.39 in Q2 2016 from $1.20 in Q2 2015, indicating strong operational performance excluding certain items.
- 5Recall charges related to the Rejuvenate and ABG II hip stems decreased significantly, falling 75.0% to $28 million in Q2 2016 from $112 million in Q2 2015, although a substantial liability remains.
- 6The company completed two significant acquisitions in April 2016: Sage Products for approximately $2.875 billion and Physio-Control for approximately $1.308 billion, significantly increasing goodwill and intangible assets.
- 7Stryker issued $3.5 billion in senior unsecured notes in March 2016, increasing its total debt significantly, which contributed to higher interest expenses.